Dolby Laboratories financials
$57.93−0.45%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Sep 26 | FY24 Sep 27 | FY23 Sep 29 | FY22 Sep 30 | FY21 Sep 24 | FY20 Sep 25 | FY19 Sep 27 | FY18 Sep 28 | FY17 Sep 29 | FY16 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.35B | $1.27B | $1.30B | $1.25B | $1.28B | $1.16B | $1.24B | $1.05B | $1.08B | $1.03B |
| Gross profit | $1.19B | $1.13B | $1.15B | $1.11B | $1.15B | $1.02B | $1.08B | $927.0M | $961.6M | $916.8M |
| Gross margin | 88.1% | 89.0% | 88.3% | 88.7% | 89.9% | 87.4% | 87.0% | 87.9% | 89.0% | 89.4% |
| Operating income | $265.0M | $258.3M | $215.8M | $206.6M | $330.5M | $218.7M | $257.1M | $183.5M | $247.1M | $231.8M |
| Net income | $255.0M | $261.8M | $200.7M | $184.1M | $310.2M | $231.4M | $255.2M | $41.7M | $206.5M | $185.9M |
| Net margin | 18.9% | 20.6% | 15.4% | 14.7% | 24.2% | 19.9% | 20.5% | 4.0% | 19.1% | 18.1% |
| Diluted EPS | $2.62 | $2.69 | $2.05 | $1.81 | $2.97 | $2.25 | $2.44 | $0.39 | $2.00 | $1.81 |
| EBITDA | $367.8M | $340.3M | $345.4M | $305.7M | $436.6M | $332.4M | $378.8M | $264.3M | $344.3M | $318.2M |
| Operating cash flow | $472.2M | $327.3M | $367.1M | $318.6M | $447.8M | $343.8M | $327.7M | $352.2M | $377.8M | $360.1M |
| Free cash flow | $435.9M | $297.2M | $336.7M | $270.6M | $393.3M | $277.5M | $231.4M | $279.4M | $278.2M | $259.3M |
| Diluted shares | 97.5M | 97.3M | 97.7M | 102.0M | 104.6M | 102.9M | 104.6M | 107.0M | 103.3M | 102.4M |
Balance sheet
| Period end | Sep 26 | Sep 27 | Sep 29 | Sep 30 | Sep 24 | Sep 25 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $701.9M | $482.0M | $745.4M | $620.1M | $1.23B | $1.07B |
| Short-term investments | $703.0K | $0.00 | $139.1M | $189.2M | $38.8M | $46.9M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $3.23B | $3.11B | $2.98B | $2.69B | $3.11B | $2.92B |
| Total liabilities | $595.8M | $623.0M | $607.6M | $438.5M | $501.5M | $478.9M |
| Shareholders' equity | $2.63B | $2.49B | $2.37B | $2.25B | $2.60B | $2.44B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology